Doctors can prescribe a new treatment that can reduce gum shedding and reduce the risk of gum infection, the American Academy of Orthopaedic Surgeons has announced.
The new treatment, called gum reduction, is being tested by several hospitals and centers in the U.S. and could be rolled out in Canada by the end of the year.
The treatment has been shown to have some success in other populations and is a way to reduce the risks of infections and infections in the future.
Doctors also have reported success in reducing gum swelling after surgery.
“Gum shedding is a common complication of surgery, and there are several options to reduce this,” Dr. Anthony Fauci, chief medical officer of the Orthopod, said in a statement.
“But the most effective way to prevent this is through gum reduction.”
The new drug is a non-prescription drug called dronabinol, a combination of THC and acetaminophen, that was approved by the U-M Department of Veterans Affairs in March 2017.
It has been in use since 2009, according to the U’s National Center for Advancing Translational Sciences.
Dronabinols are usually taken orally and have shown to reduce pain and swelling, according the National Institute on Drug Abuse.
Doctors can also prescribe the drug for other conditions.
The drug was approved for use in patients with cancer and glaucoma.
Dopamine, a neurotransmitter that regulates the pleasure centers of the brain, is involved in pain and relaxation.
The Drug Enforcement Administration has classified dronabellol as a Schedule 1 drug, meaning it’s not considered dangerous by the federal government.
It was first approved by Congress in 1998 and is approved by one FDA advisory panel.
Faucs approval of the new treatment comes amid growing concerns about the effectiveness of oral dronabetol.
In April, the FDA approved the first drug, which had to be taken by mouth, to reduce swelling and swelling-related pain in patients undergoing skin graft surgery.
That same month, the Food and Drug Administration also approved a new oral drug, also called nabilone, to help treat chronic pain.
The FDA said nabilones are more effective than oral dralabels but are less effective at reducing pain.
In the new drug, researchers have focused on the brain.
Researchers have not yet proven it works in patients who are already in pain.
They have only shown that nabilons work by reducing pain and improving brain function.
Drons use has also been studied in rats, mice and a dog, the researchers said.
“We are hoping to show that dronas effect in humans can be broadly replicated in humans,” Faucci said.
The research was published in the journal Neuron.
For more health news, click here.
